Mild hydrochloric acid hydrolysis of i-carrageenan
from Eucheuma spinosum yielded two
oligosaccharides of sulfated tetrasaccharide structure. These were
characterized by Fourier Transform Infrared Spectroscopy (FT-IR), Nuclear
Magnetic Resonance (NMR) and Electrospray Ionization Mass Spectrometry (ESIMS).
Both oligosaccharides have structure of b-D-galactopyranose(Galp)4S-(1→4)-α-D-AnGalp2S-(1→3)-b-D-galactopyranose Galp)4S-(1→4)-α-D-AnGalp2S-(1→3). Application of the resulting oligosaccharides on protein
delivery system in terms of encapsulation efficiency was performed.
References
[1]
H. Yuan, J. Song, X. Li, N. Li and J. Dai, “Immunomodulation and Antitumor Activity of [κappa]-Carrageenan Oligosaccharides,” Cancer Letters, Vol. 243, No. 2, 2006, pp. 228-234. http://dx.doi.org/10.1016/j.canlet.2005.11.032
[2]
N. Volpi and F. Maccari, “Structural Characterization and Antithrombin Activity of Dermatan Sulfate Purified from Marine Clam Scapharca inaequivalvis,” Glycobiology, Vol. 19, No. 4, 2009, pp. 356-367. http://dx.doi.org/10.1093/glycob/cwn140
[3]
H. Zhao, H. Liu, Y. Chen, X. Xin, J. Li, Y. Hou, Z. Zhang, X. Zhang, C. Xie and M. Geng, “Oligomannurarate Sulfate, A Novel Heparanase Inhibitor Simultaneously Targeting Basic Fibroblast Growth Factor, Combats Tumor Angiogenesis and Metastasis,” Cancer Research, Vol. 66, No. 17, 2006, pp. 8779-8787. http://dx.doi.org/10.1158/0008-5472.CAN-06-1382
[4]
J. H. Fitton, M. R. Irhimeh and J. Teas, “14 Marine Algae and Polysaccharides with Therapeutic Applications,” In: C. J. Barrow and F. Shahidi, Eds., Marine Nutraceuticals and Functional Foods, CRC Press, 2008, p. 345.
[5]
Q. H. Hou, W. D. Song, H. Wang and L. L. Ji, “Antidiabetic Effect of Thallus laminariae Oligosaccharide on Type 2 Diabetic Rats,” Journal of Zhanjiang Ocean University, Vol. 29, No. 4, 2009, pp. 46-50.
[6]
N. R. Sudarshan, D. G. Hoover and D. Knorr, “Antibacterial Action of Chitosan,” Food Biotechnology, Vol. 6, No. 3, 1992, pp. 257-272. http://dx.doi.org/10.1080/08905439209549838
[7]
M. N. Alekshun and S. B. Levy, “Targeting Virulence to Prevent Infection: To Kill or Not to Kill?” Drug Discovery Today: Therapeutic Strategies, Vol. 1, No. 4, 2004, pp. 483-489. http://dx.doi.org/10.1016/j.ddstr.2004.10.006
[8]
W. Xie, P. Xu and Q. Liu, “Antioxidant Activity of Water-Soluble Chitosan Derivatives,” Bioorganic & Medicinal Chemistry Letters, Vol. 11, No. 13, 2001, pp. 1699-1701. http://dx.doi.org/10.1016/S0960-894X(01)00285-2
[9]
J. Ji, L. C. Wang, H. Wu and H. M. Luan, “Bio-Function Summary of Marine Oligosaccharides,” International Journal of Biology, Vol. 3, No. 1, 2011, pp. 75-86.
[10]
H. Yuan and J. Song, “Preparation, Structural Characterization and in Vitro Antitumor Activity of Kappa-Carrageenan Oligosaccharide Fraction from Kappaphycus striatum,” Journal of Applied Phycology, Vol. 17, No. 1, 2005, pp. 7-13. http://dx.doi.org/10.1007/s10811-005-5513-8
[11]
G. Yu, H. Guan, A. S. Ioanoviciu, S. A. Sikkander, C. Thanawiroon, J. K. Tobacman, T. Toida and R. J. Linhardt, “Structural Studies on κ-Carrageenan Derived Oligosaccharides,” Carbohydrate Research, Vol. 337, 2002, pp. 433-440. http://dx.doi.org/10.1016/S0008-6215(02)00009-5
[12]
B. M. Henares, E. P. Enriquez, F. M. Dayrit and N. R. L. Rojas, “Iota-Carrageenan Hydrolysis by Pseudoalteromonas carrageenovora IFO12985,” Philippine Journal of Science, Vol. 139, No. 2, 2010, pp. 131-138.
[13]
X. Hu, X. Jiang, E. Aubree, P. Boulenguer and A. T. Critchley, “Preparation and in Vivo. Antitumor Activity of κ-Carrageenan Oligosaccharides,” Pharmaceutical Biology, Vol. 44, No. 9, 2006, pp. 646-650. http://dx.doi.org/10.1016/S0008-6215(02)00009-5
[14]
M. Guibet, S. Colin, T. Barbeyron, S. Genicot, B. Kloareg, G. Michel and W. Helbert, “Degradation of λ-carrageenan by Pseudoalteromonas carrageevora λ-carrageenase: A New Family of Glycoside Hydrolases Unrelated to κand ι-Carrageenases,” Biochemical Journal, Vol. 404, 2007, pp. 105-114. http://dx.doi.org/10.1042/BJ20061359
[15]
C. Aguzzi, M. C. Bonferoni, M. R. O. Fortich, S. Rossi, F. Ferrari and C. Caramella, “Influence of Complex Solubility on Formulations Based on Lambda Carrageenan and Basic Drugs,” AAPS PharmSciTech, Vol. 3, No. 3, 2003, pp. 83-89. http://dx.doi.org/10.1007/BF02830625
[16]
A. M. Garcia and E. S. Ghaly, “Preliminary Spherical Agglomerates of Water Soluble Drug Using Natural Polymer and Cross-Linking Technique,” Journal of Controlled Release, Vol. 4, No. 30, 1996, pp. 179-186. http://dx.doi.org/10.1016/0168-3659(95)00179-4
[17]
O. Sipahigil and B. Dortunc, “Preparation and in Vitro Evaluation of Verapamil HCl and Ibuprofen Containing Carrageenan Beads,” International Journal of Pharmaceutics, Vol. 228, No. 1, 2001, pp. 119-128. http://dx.doi.org/10.1016/S0378-5173(01)00814-6
[18]
Y. Ozsoy and N. Bergisadi, “Preparation of Mefenamic Acid Sustained Release Beads Based on Kappa-Carrageenan,” Bollettino Chimico Farmaceutico, Vol. 139, No. 3, 2000, pp. 120-123.
[19]
M. R. Mangione, D. Giacomazza, G. Cavallaro, D. Bulone, V. Martorana and P. L. San Biagio, “Relation between Structural and Release Properties in a Polysaccharide Gel System,” Biophysical Chemistry, Vol. 129, No. 1, 2007, pp. 18-22. http://dx.doi.org/10.1016/j.bpc.2007.04.013
[20]
G. Ruiz and E. S. Ghaly, “Mucoadhesive Delivery Systems Using Carrageenan and Eudragit RLPO,” VitaeColumbia, Vol. 13, No. 1, 2006, pp. 31-39.
[21]
V. K. Gupta, M. Hariharan, T. A. Wheatley and J. C. Price, “Controlled-Release Tablets from Carrageenans: Effect of Formulation, Storage and Dissolution Factors,” European Journal of Pharmaceutics and Biopharmaceutics, Vol. 51, No. 3, 2001, pp. 241-248. http://dx.doi.org/10.1016/S0939-6411(01)00135-7
[22]
A. Pourjavadi, Sh. Barzegar and F. Zeidabadi, “Synthesis and Properties of Biodegradable Hydrogels of κ-Carrageenan Grafted Acrylic Acid-co-2-acrylamido-2-methylpropanesulfonic Acid as Candidates for Drug Delivery Systems,” Reactive and Functional Polymers, Vol. 67, No. 7, 2007, pp. 644-654. http://dx.doi.org/10.1016/j.reactfunctpolym.2007.04.007
[23]
WHO, “Evaluation of Certain Food Additives and Contaminants,” Sixty-Eighth Report of the Joint FAO/WHO Expert Committee on Food Additives, WHO Technical Report Series 947, 2007, pp. 32-33.
[24]
W. M. Heller, “The United States Pharmacopeia,” 22nd Edition, 12601Twinbrook Parkway, Rockville, 1990.
[25]
A. V. Briones and T. Sato, “Ability of Chitosan/Carrageenan Complex to Encapsulate Bovine Serum Albumin (BSA) for Potential Use in Protein Delivery,” Asian Journal of Biological and Life Sciences, Vol. 2, No. 2, 2013, pp. 163-169.
[26]
S. H. Knutsen, D. E. Myslabodski, B. Larsen and A. I. Usov, “A Modified System of Nomenclature for Red Algal Galactans,” Botanica Marina, Vol. 37, No. 2, 1994, pp. 163-169. http://dx.doi.org/10.1515/botm.1994.37.2.163
[27]
C. W. Greer, C. Rochas and W. Yaphe, “Iota-Carrageenan Oligosaccharides as Model Compounds for Structural Analysis of Iota-Carrageenan by 13C-NMR Spectroscopy,” Botanica Marina, Vol. 28, 1985, pp. 9-14. http://dx.doi.org/10.1515/botm.1985.28.1.9
[28]
C. Mireles, M. Martino, J. Bouzas and J. A. Torres, “Complex Formation of Chitosan and Naturally Occurring Polyanions,” In: C. J. Brine, P. A. Sandford and J. P. Zikakis Eds., Advances in Chitin and Chitosan, Elsevier Applied Science, London, 1991, pp. 506-515.
